Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.60 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.56 |
| ▸ | CASP1 | P29466 | 6/20 | 0.55 |
| ▸ | CTSK | P43235 | 3/20 | 0.50 |
| ▸ | TACR1 | P25103 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4910499 | 1.00 | CTSL (0.60) | CTSLSIRT2CASP1CTSKTACR1 | |
| SCHEMBL8723888 | 0.92 | SIRT2 (0.58) | CTSLSIRT2CASP1CTSKMEN1 | |
| SCHEMBL6946904 | 0.90 | CTSL (0.61) | CTSLSIRT2CASP1CTSKTACR1 | |
| SCHEMBL1025916 | 0.90 | CTSL (0.61) | CTSLSIRT2CASP1CTSKTACR1 | |
| SCHEMBL20211867 | 0.90 | CTSL (0.61) | CTSLSIRT2CASP1CTSKTACR1 | |
| SCHEMBL11153005 | 0.90 | CTSL (0.61) | CTSLSIRT2CASP1CTSKTACR1 | |
| SCHEMBL30537759 | 0.90 | CTSL (0.51) | CTSLSIRT2CASP1CTSKMEN1 | |
| SCHEMBL8765287 | 0.89 | CASP1 (0.57) | CTSLCASP1CTSKTACR1MEN1 | |
| SCHEMBL11893028 | 0.89 | FOLH1 (0.58) | SIRT2CASP1CTSKTACR1 | |
| SCHEMBL7373019 | 0.89 | FOLH1 (0.58) | SIRT2CASP1CTSKTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090916-A1 | 2-Amino-4-[(1S,2R)-2-(2,5-dimethoxyphenyl)-2-hydroxy-1-methyl-ethylcarbamoyl]butyric acid, aka gamma-L-glutamyl-1R,2S-methoxamine; prodrug of 1R,2S-methoxamine that is converted within the kidney tubules into its active form; transdermal administration; coupling methoxamine with glutamic acid alcohol | NORGINE EUROPE B.V. (NL) | 2008-04-17 | — | — | US | disclosed |
| EP-1841728-A1 | COMPOUNDS FOR TREATING URINARY INCONTINENCE | Norgine Europe BV (NL) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006079809-A1 | COMPOUNDS FOR TREATING URINARY INCONTINENCE | NORGINE EUROPE BV (NL) | 2006-08-03 | — | — | WO | disclosed |
| EP-0071926-B1 | NEW RIBOFURANURONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-08 | — | — | EP | disclosed |
| US-4479942-A | Tetrahydrofurnancarboxylic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-30 | — | — | US | disclosed |
| EP-0071926-A1 | New ribofuranuronic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090916-A1 | 2-Amino-4-[(1S,2R)-2-(2,5-dimethoxyphenyl)-2-hydroxy-1-methyl-ethylcarbamoyl]butyric acid, aka gamma-L-glutamyl-1R,2S-methoxamine; prodrug of 1R,2S-methoxamine that is converted within the kidney tubules into its active form; transdermal administration; coupling methoxamine with glutamic acid alcohol | GLS, GLRB, CHRM1 | CTSL 3348/4885SIRT2 1858/4885CASP1 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.